Hepatic Interferon Receptor Mrna Expression: Clinical Relevance and Its Relationship with Effectiveness of Interferon plus Ribavirin Therapy in Patients with Genotype 1B Hepatitis C Virus Infection
Free accessResearch articleFirst published online January, 2006
Hepatic Interferon Receptor Mrna Expression: Clinical Relevance and Its Relationship with Effectiveness of Interferon plus Ribavirin Therapy in Patients with Genotype 1B Hepatitis C Virus Infection
Hepatic expression of interferon (IFN) receptor mRNA has been shown to correlate with the effectiveness of IFN monotherapy in patients with chronic hepatitis C virus (HCV) infection. We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection.
Methods
A total of 42 naive patients who had chronic HCV-1b infection were treated with IFN alpha-2b 3 MU or 5 MU three times weekly plus RBV for 24 weeks. Hepatic IFNAR2c mRNA was quantified by real-time RT-PCR.
Results
There was no significant difference in the mean expression level of IFNAR2c mRNA between patients with sustained virological response (SVR) and non-SVR (0.069 ±0.042 versus 0.053 ±0.033, P=0.182). Multiple linear regression analysis showed that lower fibrosis scores (P=0.006) and younger age (P=0.03) were associated with hepatic IFNAR2c mRNA expression with r2=0.34.
Conclusions
Hepatic IFNAR2c mRNA expression may not be useful for predicting the response to IFN plus RBV therapy in patients with HCV-1b infection, but appeared to correlate inversely with the fibrosis stage and age.
References
1.
AlterM.J.Epidemiology of hepatitis C in the West.Semin Liver Dis1995; 15: 5–14.
2.
PoynardT., BedossaP., OpolonP.Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.Lancet1997; 349: 825–832.
3.
KiyosawaK., SodeyamaT., TanakaE.Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.Hepatology1990; 12: 671–675.
4.
LeeC.M., LuS.N., ChangchienC.S.Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection.Cancer1999; 86: 1143–1150.
5.
PoynardT., MarcellinP., LeeS.S.Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.Lancet1998; 352: 1426–1432.
6.
McHutchisonJ.G., GordonS.C., SchiffE.R.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.N Engl J Med1998; 339: 1485–1492.
7.
BergT., SarrazinC., HerrmannE.Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.Hepatology2003; 37: 600–609.
8.
HungC.H., LeeC.M., LuS.N.Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.JViral Hepat2003; 10: 87–94.
9.
KaoJ.H., ChenP.J., LaiM.Y.Genotypes of hepatitis C virus in Taiwan and the progression of liver disease.J Clin Gastroenterol1995; 21: 233–237.
10.
ZeinN.N., RakelaJ., KrawittE.L.Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study group.Ann Intern Med1996; 125: 634–639.
11.
LevyD.E., Garcia-SastreA.The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion.Cytokine Growth Factor Rev2001; 12: 143–156.
12.
DomanskiP., WitteM., KellumM.Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling.J Biol Chem1995; 270: 21606–21611.
13.
ColamoniciO.R., DomanskiP.Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21.J Biol Chem1993; 268: 10895–108999.
14.
DomanskiP., ColamoniciO.R.The type-I interferon receptor. The long and short of it.Cytokine Growth Factor Rev1996; 7: 143–151.
15.
MullerU., SteinhoffU., ReisL.F.Functional role of type I and type II interferons in antiviral defense.Science1994; 264: 1918–1921.
IshimuraN., FukudaR., FukumotoS.Relationship between the intrahepatic expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases.J Gastroenterol Hepatol1996; 11: 712–717.
18.
FukudaR., IshimuraN., IshiharaS.Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy.J Gastroenterol1996; 31: 806–811.
19.
FukudaR., IshimuraN., KushiyamaY.Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver.J Hepatol1997; 26: 455–461.
20.
YatsuhashiH., YamasakiK., AritomiT.Quantitative analysis of interferon alpha/beta receptor mRNA in the liver of patients with chronic hepatitis C: correlation with serum hepatitis C virus-RNA levels and response to treatment with interferon.J Gastroenterol Hepatol1997; 12: 460–467.
21.
MoritaK., TanakaK., SaitoS.Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection.J Clin Gastroenterol1998; 26: 135–140.
22.
YatsuhashiH., FujinoT., MatsumotoT.Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.J Hepatol1999; 30: 995–1003.
23.
MoritaK., TanakaK., SaitoS.Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C.J Med Virol1999; 58: 359–365.
24.
MathaiJ., ShimodaK., BannerB.F.IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy.J Interferon Cytokine Res1999; 19: 1011–1018.
25.
YinJ.L., ShackelN.A., ZekryA.Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I.Immunol Cell Biol2001; 79: 213–221.
26.
DesmetV.J., GerberM., HoofnagleJ.H., MannsM., ScheuerP.J.Classification of chronic hepatitis: diagnosis, grading and staging.Hepatology1994; 19: 1513–1520.
27.
FujiwaraD., HinoK., YamaguchiY.Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study.J Viral Hepat2004; 11: 136–140.
28.
LauJ.Y., TamR.C., LiangT.J., HongZ.Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.Hepatology2002; 35: 1002–1009.
29.
SintchakM.D., NimmesgernE.The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors.Immunopharmacology2000; 47: 163–184.
30.
MaagD., CastroC., HongZ., CameronC.E.Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin.J Biol Chem2001; 276: 46094–46098.
31.
LanfordR.E., ChavezD., GuerraB.Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes.J Virol2001; 75: 8074–8081.
ChungJ., UchidaE., GrammerT.C., BlenisJ.STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation.Mol Cell Biol1997; 17: 6508–6516.
34.
StancatoL.F., SakatsumeM., DavidM.Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway.Mol Cell Biol1997; 17: 3833–3840.
35.
MiyajimaI., SataM., GondoK., SuzukiH., TanikawaK.Interferon accumulation in cirrhotic rat liver.J Viral Hepat1996; 3: 23–27.
